Mark Levick leads Alvotech with over 30 years of experience in the healthcare and pharmaceutical industries, blending a clinical background with deep business expertise. Most recently, he oversaw the successful approval in major markets of five of the earliest biosimilars medicines as Global Head of Biopharmaceutical Development for Sandoz, a division of Novartis. After seeing the life-changing impact that biosimilars could have, he became a passionate advocate for broader access to biologic medicines and he brings that passion to Alvotech. 

Previously Mark also held roles of increasing responsibility at Novartis in the USA and Switzerland, including SVP of Respiratory Development, VP of Clinical Development for Immunology, Transplantation and Dermatology, and Head of the Infectious Disease Clinical Science and Biologics Units, all roles in which he played a pivotal role in the approval of multiple innovative biologic medicines. He rounds out his experience with leadership positions in clinical pharmacology and translational medicine with GlaxoSmithKline in both the UK and USA.  

Prior to entering the pharmaceutical industry, Mark served as a medical reviewer at the UK’s Medicines and Healthcare Products Regulatory Agency and the European Medicines Agency, following more than 10 years practicing as a specialist physician in teaching hospitals in the UK and Australia. Mark has a medical degree from the University of Newcastle, Australia, and is board certified in both infection medicine and general medicine. He studied at the University of Cambridge in the UK as a Commonwealth scholar and holds a PhD in vaccine development from Cambridge University.

Mark Levick

With over 20 years of international experience in biotechnology, healthcare and financial services as an executive and corporate lawyer, Tanya Zharov brings with her a strong track record in business and innovation-driven global life science to Alvotech. She guides Icelandic operations and global administration, with her responsibility extending across HR, business operations, services and facilities. She also works in partnership with the CEO, Mark Levick, and members of the corporate leadership team to instill a strong sense of culture across all global locations.

Prior to joining Alvotech, she was the deputy CEO and Compliance Officer at deCODE genetics, a renowned Icelandic world leader in human genetics acquired by Amgen in 2012. A lawyer by training, she also acted as Corporate Counsel, leading the securities regulation and compliance team behind deCODE’s US IPO, the first of its kind for an Icelandic company. 

In-between her stints at deCODE, Tanya was a Founding Partner and Deputy CEO of Audur Capital, an Icelandic securities firm, where her responsibilities spanned legal affairs, wealth management, corporate finance, private equity and capital markets. She is a specialist in US and global public markets law, regulation and best practices. Early in her career, Tanya served as a Tax Partner at PricewaterhouseCoopers and she holds a Cand. Juris law degree from the University of Iceland. Tanya is a European Patent Attorney.

Tanya Zharov

Joe McClellan leads the company’s R&D functions, with overarching responsibility for bringing Alvotech’s biosimilar candidates to market. He is an insightful scientist and passionate leader, overseeing R&D operations across our sites in Iceland, Germany, Switzerland and the US. He brings with him an outstanding track record in drug development and 20 years of extensive industry experience driving forward R&D programs, while ensuring strategic and operational excellence. 

Prior to joining Alvotech, Joe worked at Wyeth and Pfizer for 17 years and developed broad experience in all areas of biologic medicine development including biosimilars, innovator biologics, pharmaceutical science, clinical development, regulatory strategy and discovery research. In his last role, he held the position of Global Head of Biosimilars Development and was the asset team lead for Pfizer’s biosimilar infliximab, IXIFI. During Joe’s tenure leading biosimilar development at Pfizer, the company secured major market approvals for 6 unique biosimilar molecules and submitted applications for 2 additional unique biosimilars that were subsequently approved. 

Joe earned a Ph.D. degree in Chemistry, with a focus in Analytical Chemistry and Mass Spectrometry, from the University of Florida. In addition, he was a Postdoctoral Fellow in Mass Spectrometry and Analytical Biochemistry at the Boston University School of Medicine and received his MBA, with a focus on innovation and business growth in high-technology industries, from Northeastern University. He holds a Bachelor of Arts in Chemistry from the College of the Holy Cross.

Joseph E. McClellan

Sean Gaskell joins Alvotech with over 15 years of industry experience, bringing deep expertise in biologic manufacturing across a variety of platforms, pharmaceutical and chemical operations, technical operations strategy, QA compliance and research chemistry. Most recently, Sean was VP of Manufacturing Operations and Site Head at AveXis and played an integral role in the transformational change of its core facility producing AAV9-based gene therapies, enabling the company to become a commercial supplier of live-saving medicines for patients with rare diseases. 

Prior to AveXis, Sean held various roles of increasing responsibility at Novartis. Most recently he was Site Head in charge of Drug Substance Bioproduction for Novartis’ Basel, Switzerland facility. He again drove the transformation of the site from clinical pilot plant to commercial manufacturing facility for both innovative and biosimilar biologics, accelerating the launch of three commercial products under his leadership. Other notable roles include strategic assistant to Novartis’ Global Head of Technical Operations, charged with developing, implementing and monitoring the company’s long-term technical operations strategy across more than 50 sites worldwide, and Process Unit Head of Chemical Operations. 

Starting out his career as a research chemist, Sean holds a Bachelor of Science with first class honors in chemistry and a PhD in organic chemistry from Loughborough University, UK. 

Sean Gaskell

Joel Morales has served as Alvotech’s Chief Financial Officer since February 2020 after holding the same role for affiliated company Alvogen since 2017. Prior to joining Alvotech he held various positions of increasing responsibility with Endo International plc., with his last position as Senior Vice President of the Generics Business Segment and Global Finance Operations. Prior to that, Joel spent ten years working for large multinational pharmaceutical companies, including Merck and Schering Plough.

Joel is a licensed certified public accountant in the State of New Jersey and has a Bachelor of Science degree in accounting from Rutgers University.

Joel Morales

Andrew Roberts leads portfolio strategy for Alvotech’s selection of pipeline assets, including overseeing several enterprise leadership functions responsible for the successful registration and partner commercialization of our biosimilars. He brings with him significant strategy experience, contributing to both originator and biosimilar strategy and development over his 18-year career in the pharmaceutical industry.

Most recently, Andrew was Senior Global Program Head for Sandoz, a division of Novartis, and led both development portfolio strategy as well as the completion of several key collaboration agreements for Sandoz's biosimilar portfolio. Prior to that role, Andrew held additional leadership positions at Novartis in charge of originator development teams in a variety of therapeutic areas and worked on portfolio strategy at the group level for the Board of Directors. He rounds out his pharmaceutical industry experience at Biogen Idec. 

Andrew holds an Executive MBA from INSEAD, a Master of Science in Nutrition and a Bachelor of Science in Biology from Louisiana State University.

Andrew Roberts

Anil Okay comes to Alvotech with an impressive track record as a general manager, P&L owner, commercial operations professional and expert negotiator, completing countless license, acquisition, supply, distribution, and sales and marketing agreements, worth >$25B. Over the course of his 15-year career in the pharmaceutical industry, Anil developed an extensive network and deep expertise in Commercial Operations, BD and M&A, which he oversees for Alvotech. Anil played an integral role in building and establishing Alvotech’s go-to-market strategy, securing partnerships in more than 100 countries worldwide. Concurrently, he started Adalvo in 2018 and built it up to becoming one of the leading B2B companies in Europe. 

Prior to his experience as CCO of Alvotech and GM and Board Member of Adalvo, Anil was Head of Global Licensing for HELM AG where he managed all partnerships for small molecules in addition to biosimilars through a joint venture with Gedeon Richter, resulting in the most successful commercial performance in the company’s 40-year history. He also held positions of increasing responsibility at Abdi Ibrahim, in various regions and functions, eventually heading all international market operations where he developed and led the successful execution of a global market entry strategy including more than 30 new markets. He began his career at Sanofi as a medical rep and transitioned to business development. 

Anil holds an MBA from the Vienna University of Economics and Business and a Master of Marketing Management from Galatasaray University. He completed a Bachelor of Engineering with a double major in Mathematics and Computer Engineering, graduating with honors. He has continued honing his skillset through various executive education programs at Harvard and INSEAD.

Anil was recognized “Leader of the Year” at the 2021 Global Generics and Biosimilars Awards.

Anil Okay

Reem Malki leads the quality functions at Alvotech, bringing almost 30 years of extensive experience as a dynamic and strategic quality leader to the company. She has a proven track record across a variety of product types including biosimilars, injectables, oral solids, medical devices and combination products. Prior to joining Alvotech she held various leadership roles at Mylan including Head of Global Quality Operations for both affiliates and third parties as well as OSD, API, injectables and biosimilars and VP of EMEA Quality Operations, among others. 

Prior to Mylan, Reem held positions of increasing responsibility in quality control at Andrx Pharmaceuticals leading up to its acquisition by Watson, most recently as Director of Quality Control. She began her career in the pharmaceutical industry at Wyeth Ayerst Laboratories and Zymark Corporation. 

Reem holds a Bachelor of Science in Chemistry from the University of Maine

Reem Malki

Ella Sigga joins Alvotech with deep expertise in human resource management and administration. With over 20 years of experience in HR-related leadership roles, she is passionate about improving employee relations, streamlining processes and increasing operational efficiency. Most recently, Ella Sigga was head of Human Resources at the EFLA Consulting Engineers, a firm focused on high quality engineering and consulting services worldwide. 

Prior to that, she was head of the Human Resources and Quality division of Reykjavík University where she was also a lecturer. During this time, she also sat on the board and was Chairman for Mannauður, the Icelandic association for people management, where she supported knowledge sharing to advance professionalism in HR management in Iceland. Ella Sigga began her career in the healthcare industry at deCODE genetics, a renowned world leader in human genetics, where she spent 14 years in roles of increasing responsibility, including Head of HR.

She completed an Advanced Management Program at IESE Business School and holds a Master of Science in International HR Management and Globalization from the University of Leicester, along with a Bachelor of Arts in Sociology and Industrial Relations from the University of Iceland.

Sigridur Elin Gudlaugsdottir

Ming Li leads key strategic initiatives, investor relations and communications as Alvotech’s Chief Strategy Officer. Over the past 20 plus years he has cultivated significant and broad experience in the pharmaceutical and biotech industries across a variety of roles in R&D, quality, operations, process improvement, finance and corporate development. 

Most recently, Ming was EVP of Corporate Development for Alvogen, a top, global generics player where he was instrumental in the company’s growth and development as one of its first employees. Prior to joining Alvogen, Ming held a leadership role at Actavis, focused on operations and process improvement.

Ming began his career as a Chemist and holds a Bachelor of Science in Chemistry from North Carolina State University. He also holds a Lean Six Sigma Black Belt Certification.  

Ming Li

Rose-Marie brings a wealth of experience as a public CIO to her role at Alvotech. Rose-Marie joins us from Sobi; an international biopharmaceutical company focused on rare diseases, arising from the merger between Biovitrum AB and Swedish Orphan International in 2010. Since 2002, Rose-Marie has held roles of increasing responsibility in the IT organization at Biovitrum/Sobi, culminating in her appointment as Group CIO four years ago. Prior to joining Biovitrum, Rose-Marie spent 10 years working for SEB, a leading Nordic bank and financial services group, in various HQ and international roles.

Rose-Marie holds a finance degree in business administration and economics from the Mittuniversitetet, Sundsvall and Härnösand.

Rose-Marie Ohlsson

Alvotech is the product of decades of collective experience as accomplished industry leaders and a shared commitment to biosimilars. It is our leaders that inspire our teams to action.

One mission, decades of experience.